EIKNEikon TherapeuticsSigning up patients
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Advanced Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 156 (planned)
- Started
- Dec 11, 2023
- Main results expected
- Jun 1, 2027
- Fully finished
- Dec 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of subjects with adverse events, treatment emergent adverse events or serious adverse events
Measured over: Consent to 30 + 7 days post last dose of IMP1734
Maxim Tolerated Dose or Recommended Dose for Expansion
Measured over: DLT period is from the first dose of the study drug until the last day of the first cycle
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06253130 · record last updated 2026-06-15 · checked 2026-11-09 15:47 UTC